Table 2. Number of men avoiding biopsy and diagnosis rates for a target definition for significance on TTPM-biopsy of definition 1 (Gleason ⩾4+3 and/or maximum cancer core length ⩾6mm) for each MRI score.
|
mpMRI score threshold for positive |
||
|---|---|---|
| mpMRI SCORE ⩾3 | mpMRI SCORE ⩾4 | |
| Avoid biopsy | 14% (35/249) | 48% (120/249) |
| Biopsy | 86% (214/249) | 52% (129/249) |
| Overdiagnosed insignificant cancer (of those undergoing a repeat biopsy based on mpMRI) | 41% (89/214) | 31% (40/129) |
| Diagnosed Significant cancer (of those undergoing a repeat biopsy based on mpMRI) | 47% (100/214) | 64% (83/129) |
| Underdiagnosed significant cancer (of those not undergoing a repeat biopsy based on mpMRI) | 9% (3/35) | 8% (20/120) |
| False positive on mpMRI (of those undergoing a repeat biopsy based on mpMRI) | 12% (25/214) | 5% (6/129) |
| Sensitivity (95% confidence interval) | 97.1% (91.7–99.4%) | 80.6% (71.6–87.7%) |
| Specificity (95% confidence interval) | 21.9% (15.5–29.5%) | 68.5% (60.3–75.9%) |
| NPV (95% confidence interval) | 91.4% (76.9–98.2%) | 83.3% (75.4–89.5%) |
| PPV (95% confidence interval) | 46.7% (39.9–53.7%) | 64.3% (55.4–72.6%) |
| AUROC (95% confidence interval) | 0.60 (0.56–0.63) | 0.75 (0.69–0.80) |
Abbreviations: AUROC=area under receiver-operating characteristic; mpMRI=multiparametric magnetic resonance imaging; NPV=negative predictive value; PPV=positive predictive value.